nasdaq.com
Cure8 news brief
FDA Approves Lilly's Omvoh For Crohn's Disease Treatment - Nasdaq
Medications
Mirikizumab
IL-23 inhibitor
Regulatory Update
Adult patients
Patients On Biologics
Clinicians
Researchers
Why This Matters
A newly FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderately to severely active Crohn's disease another targeted treatment option. It's the same IL-23–targeting drug already approved for ulcerative colitis, so clinicians and patients will be interested in how it compares to existing therapies.
Who Should Pay Attention
Adults with moderate-to-severe Crohn's disease, patients considering or on biologic therapy, gastroenterologists and IBD clinicians, and researchers focused on IL-23–targeted treatments.
Study Snapshot
Story typeResearch news
Evidence typeRegulatory update
Source depthFull source text
What To Know
The FDA has approved Omvoh (mirikizumab-mrkz) for adults with moderately to severely active Crohn's disease. This is the same IL-23p19–targeting biologic that Lilly previously had approved for ulcerative colitis.
The article reports that Omvoh reduces gut inflammation by targeting interleukin-23p19 and notes Lilly submitted global regulatory applications and disclosed two-year Phase 3 efficacy data at approval. Practical context: This approval adds another FDA-approved biologic option for adults with moderate-to-severe Crohn's disease.
It may be most relevant to people considering biologic therapies, clinicians who prescribe IBD treatments, and researchers tracking IL-23–targeting drugs. The Nasdaq piece is a brief news report summarizing Lilly's announcement and does not include detailed trial results, safety information, or prescribing guidance.
Next steps if you want details: Look for the FDA approval letter, Lilly's full press release, and peer-reviewed Phase 3 publications or conference presentations to see detailed efficacy, safety, and recommended dosing information.
Keep In Mind
The article is a short Nasdaq summary of RTTNews/Lilly announcements and does not include detailed trial data, safety profiles, or prescribing information. For clinical decisions, consult the FDA labeling and peer-reviewed trial reports. Regulatory approvals in other regions are pending.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationnasdaq.com
Indexed viaGoogle News
Source typeResearch news
PublishedJan 16, 2025, 3:44 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Lilly gains US FDA approval for Omvoh to treat Crohn’s disease
FDA approval means mirikizumab (Omvoh) is now an available biologic option in the US for adults with moderately to severely active Crohn’s disease, especially for people who did not respond to standard treatments. It may...
J&J adds to IL-23 options in Crohn's after FDA approval
A newly FDA‑approved IL‑23 drug for Crohn’s may increase treatment options for people with IBD, including an IV and a subcutaneous formulation. The approval could affect switching decisions for patients not responding to...
Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment
A newly approved biologic, Omvoh (mirikizumab), gives another FDA‑approved treatment option for adults with moderate to severe Crohn’s disease and adds to Lilly’s role in IBD care.